Swiss National Bank
GEVA

Swiss National Bank’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Swiss National Bank’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28,530
Closed -$2.78M – 2630
2015
Q1 		$2.78M Buy
28,530
+7,530
+36% +$797K 0.01% 1089
2014
Q4 		$1.95M Buy
21,000
+600
+3% +$47.3K 0.01% 1276
2014
Q3 		$1.4M Sell
20,400
-500
-2% -$35.8K 0.01% 1448
2014
Q2 		$2.19M Hold
20,900
– – 0.01% 1196
2014
Q1 		$1.73M Buy
20,900
+5,800
+38% +$536K 0.01% 1301
2013
Q4 		$977K Hold
15,100
– – ﹤0.01% 1522
2013
Q3 		$956K Buy
15,100
+1,300
+9% +$64K ﹤0.01% 1478
2013
Q2 		$580K Buy
+13,800
New +$629K ﹤0.01% 1803

Swiss National Bank's GEVA Position: Q2 2015 in Review

Swiss National Bank sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 28,530 shares — an estimated $2.78M sold.

Swiss National Bank first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.78M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Swiss National Bank reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Swiss National Bank sold 28,530 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $2.78M.
  • Swiss National Bank first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Swiss National Bank's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.78M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Swiss National Bank's 13F filing for Q2 2015, filed 5 Aug 2015.